NEWS
-
2021/01/10 Correctseq
CorrectSequence Therapeutics (Correctseq), a pioneer gene editing biotechnology company, recently completed an angel round of financing of 40 million RMB (approximately USD 6 million). This round of financing is jointly led by Zoo Capital and New Alliance Capital, followed by Sequoia China and TF Capital, and signed a global exclusive permanent authorization agreement with ShanghaiTech University with a total amount of more than 170 million RMB (approximately USD 25 million).
-
2021/01/04 Correctseq
Co-founder of Correctseq, Professor Li Yang was invited to participate in the theme interview of the 6th BiG IMPACT annual conference on " Transforming from Papers to Product, the Difficulties and Path Breakthrough!".